Ping Liao
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Research Interests
Ping Liao has a total of 29 co-authors. Here are the top co-authors by number of shared publications:
- Wen-Jing Wang
Department of Molecular Biology for Public Health, Shanghai Municipal Center for Disease Control and Prevention, 1380 Zhong Shan Xi Road, Shanghai, 200336, China
5 shared publications - Cha-Zhen Liu
Department of Molecular Biology for Public Health, Shanghai Municipal Center for Disease Control and Prevention, 1380 Zhong Shan Xi Road, Shanghai, 200336, China
2 shared publications - Ann W. Hsing
Stanford Cancer Center, Stanford University, Palo Alto, CA, US
1 shared publication - Asif Rashid
Department of Pathology, The University of Texas MD Anderson Cancer Center, Houston, TX USA
1 shared publication Chun-Yan Zhang
1 shared publicationCui-Qin Xiang
1 shared publication
Latest Publications
- Open Access
Identification of Serum Biomarkers for Biliary Tract Cancers by a Proteomic Approach Based on Time-of-Flight Mass Spectrometry
Biliary tract cancers (BTCs) are lethal malignancies currently lacking satisfactory methods for early detection and accurate diagnosis. Surface-enhanced laser desorption/ionization time-of-flight mass spectrometry (SELDI-TOF-MS) is a promising diagnostic tool for this disease. In this pilot study, sera samples from 50 BTCs and 30 cholelithiasis patients as well as 30 healthy subjects from a population-based case-control study were randomly grouped into training set (30 BTCs, 20 cholelithiasis and 20 controls), duplicate of training set, and blind set (20 BTCs, 10 cholelithiasis and 10 controls); all sets were analyzed on Immobilized Metal Affinity Capture ProteinChips via SELDI-TOF-MS. A decision tree classifier was built using the training set and applied to all test sets. The classification tree constructed with the 3,400, 4,502, 5,680, 7,598, and 11,242 mass-to-charge ratio (m/z) protein peaks had a sensitivity of 96.7% and a specificity of 85.0% when comparing BTCs with non-cancers. When applied to the duplicate set, sensitivity was 66.7% and specificity was 70.0%, while in the blind set, sensitivity was 95.0% and specificity was 75.0%. Positive predictive values of the training, duplicate, and blind sets were 82.9%, 62.5% and 79.2%, respectively. The agreement of the training and duplicate sets was 71.4% (Kappa = 0.43, u = 3.98, P < 0.01). The coefficient of variations based on 10 replicates of one sample for the five differential peaks were 15.8–68.8% for intensity and 0–0.05% for m/z. These pilot results suggest that serum protein profiling by SELDI-TOF-MS may be a promising approach for identifying BTCs but low assay reproducibility may limit its application in clinical practice.
Open AccessIdentification of Serum Biomarkers for Biliary Tract Cancers by a Proteomic Approach Based on Time-of-Flight Mass Spectrometry
Biliary tract cancers (BTCs) are lethal malignancies currently lacking satisfactory methods for early detection and accurate diagnosis. Surface-enhanced laser desorption/ionization time-of-flight mass spectrometry (SELDI-TOF-MS) is a promising diagnostic tool for this disease. In this pilot study, sera samples from 50 BTCs and 30 cholelithiasis patients as well as 30 healthy subjects from a population-based case-control study were randomly grouped into training set (30 BTCs, 20 cholelithiasis and 20 controls), duplicate of training set, and blind set (20 BTCs, 10 cholelithiasis and 10 controls); all sets were analyzed on Immobilized Metal Affinity Capture ProteinChips via SELDI-TOF-MS. A decision tree classifier was built using the training set and applied to all test sets. The classification tree constructed with the 3,400, 4,502, 5,680, 7,598, and 11,242 mass-to-charge ratio (m/z) protein peaks had a sensitivity of 96.7% and a specificity of 85.0% when comparing BTCs with non-cancers. When applied to the duplicate set, sensitivity was 66.7% and specificity was 70.0%, while in the blind set, sensitivity was 95.0% and specificity was 75.0%. Positive predictive values of the training, duplicate, and blind sets were 82.9%, 62.5% and 79.2%, respectively. The agreement of the training and duplicate sets was 71.4% (Kappa = 0.43, u = 3.98, P < 0.01). The coefficient of variations based on 10 replicates of one sample for the five differential peaks were 15.8–68.8% for intensity and 0–0.05% for m/z. These pilot results suggest that serum protein profiling by SELDI-TOF-MS may be a promising approach for identifying BTCs but low assay reproducibility may limit its application in clinical practice.
- 1 January 2010
- Vol. 32 (1) , 33-6
[Application of serum protein profiling in diagnosis, prognosis and evaluation of curative effect of pancreatic adenocarcinoma].
To establish decision tree and logistic regression classification models for diagnosing pancreatic adenocarcinoma (PaCa) and for screening serum biomarkers related to evaluation of different stages and curative effects. Serum samples obtained from subjects with pancreatic adenocarcinoma (n = 58) and normal pancreas (n = 51) were applied to strong anion exchange chromatography (SAX2) chips for protein profiling by SELDI-TOF-MS to screen multiple serum biomarkers. Biomarker Wizard software and several statistical methods including algorithm of decision tree, logistic regression and ROC curves were used to construct the decision tree or logistic regression classification models. Average of 61 mass peaks were detected at the molecular range of 2000-30,000, ten decision trees with the highest cross validation rate were chosen to construct the classification models, which can differentiate PaCa from normal pancreas with a sensitivity of 83.3% and a specificity of 100%. Logistic regression was used to achieve the AUC (0.976 +/- 0.011, P < 0.001) with a sensitivity of 77.6% - 91.4% and a specificity of 92.2% - 100%. Six mass peaks were combined by logistic regression to achieve the AUC 0.897 +/- 0.054, 0.978 +/- 0.021 and 0.792 +/- 0.107 (P < 0.05) in the three groups (patients at stage I and II, stage II and III, stage III and IV). One mass peak (M/Z 4,016) was screened (P < 0.05) significantly between the preoperative and postoperative PaCa samples and the intensity decreased weeks after operation. Decision tree and logistic regression classification models of the mass peaks screened by SELDI-TOF-MS serum profiling can be used to differentiate pancreatic adenocarcinoma from normal pancreas, and is superior to CA 199. The detected mass peaks are helpful for the evaluation of curative effect and prognosis of pancreatic adenocarcinoma.
- 1 January 2010
- Vol. 32 (1) , 33-6
[Application of serum protein profiling in diagnosis, prognosis and evaluation of curative effect of pancreatic adenocarcinoma].
To establish decision tree and logistic regression classification models for diagnosing pancreatic adenocarcinoma (PaCa) and for screening serum biomarkers related to evaluation of different stages and curative effects. Serum samples obtained from subjects with pancreatic adenocarcinoma (n = 58) and normal pancreas (n = 51) were applied to strong anion exchange chromatography (SAX2) chips for protein profiling by SELDI-TOF-MS to screen multiple serum biomarkers. Biomarker Wizard software and several statistical methods including algorithm of decision tree, logistic regression and ROC curves were used to construct the decision tree or logistic regression classification models. Average of 61 mass peaks were detected at the molecular range of 2000-30,000, ten decision trees with the highest cross validation rate were chosen to construct the classification models, which can differentiate PaCa from normal pancreas with a sensitivity of 83.3% and a specificity of 100%. Logistic regression was used to achieve the AUC (0.976 +/- 0.011, P < 0.001) with a sensitivity of 77.6% - 91.4% and a specificity of 92.2% - 100%. Six mass peaks were combined by logistic regression to achieve the AUC 0.897 +/- 0.054, 0.978 +/- 0.021 and 0.792 +/- 0.107 (P < 0.05) in the three groups (patients at stage I and II, stage II and III, stage III and IV). One mass peak (M/Z 4,016) was screened (P < 0.05) significantly between the preoperative and postoperative PaCa samples and the intensity decreased weeks after operation. Decision tree and logistic regression classification models of the mass peaks screened by SELDI-TOF-MS serum profiling can be used to differentiate pancreatic adenocarcinoma from normal pancreas, and is superior to CA 199. The detected mass peaks are helpful for the evaluation of curative effect and prognosis of pancreatic adenocarcinoma.
- 25 March 2008
- Vol. 88 (12) , 858-60
[Proteomic analysis in combination with CT diagnosis to distinguish renal cell carcinoma from renal benign masses].
To identify the proteomic differences between renal cell carcinoma (RCC) and renal benign masses and to evaluate the diagnostic value of parallel and serial test combining with CT and surface enhanced laser desorption/ionization-time of flight-mass spectrometry (SELDI-TOF-MS). Serum samples were collected from 96 patients with renal tumors, 62 RCC cases and 34 renal benign mass cases, all of which had been evaluated by CT before surgery. The sera were analyzed using IMAC-Cu2+ ProteinChip system by SELDI-TOF-MS. The decision tree was generated by Biomark Pattern based on the sera of 42 RCC cases and 22 renal benign mass cases and was blind-tested by the rest sera samples. The parallel method and serial method combining CT and SELDI were also used to distinguish RCC and renal benign masses. The sensitivity and specificity of the decision tree were 85.7% (36/42) and 90.9% (20/22) respectively. The sensitivity and specificity of the double-blind test were 75.0% (15/20) and 83.3% (10/12) respectively. CT showed higher sensitivity but lower specificity in detecting RCC. While combining CT with SELDI-TOF-MS, the sensitivity and specificity could be improved. Three peaks with the molecular weights of 4657.56, 2955.95, and 3278.00 were detected which are potentially useful for differentiating RCC and renal benign masses. Using serial method combining CT and the decision tree based on these three proteins improves the sensitivity and positive predictive values of diagnosing RCC to 100%.
- 25 March 2008
- Vol. 88 (12) , 858-60
[Proteomic analysis in combination with CT diagnosis to distinguish renal cell carcinoma from renal benign masses].
To identify the proteomic differences between renal cell carcinoma (RCC) and renal benign masses and to evaluate the diagnostic value of parallel and serial test combining with CT and surface enhanced laser desorption/ionization-time of flight-mass spectrometry (SELDI-TOF-MS). Serum samples were collected from 96 patients with renal tumors, 62 RCC cases and 34 renal benign mass cases, all of which had been evaluated by CT before surgery. The sera were analyzed using IMAC-Cu2+ ProteinChip system by SELDI-TOF-MS. The decision tree was generated by Biomark Pattern based on the sera of 42 RCC cases and 22 renal benign mass cases and was blind-tested by the rest sera samples. The parallel method and serial method combining CT and SELDI were also used to distinguish RCC and renal benign masses. The sensitivity and specificity of the decision tree were 85.7% (36/42) and 90.9% (20/22) respectively. The sensitivity and specificity of the double-blind test were 75.0% (15/20) and 83.3% (10/12) respectively. CT showed higher sensitivity but lower specificity in detecting RCC. While combining CT with SELDI-TOF-MS, the sensitivity and specificity could be improved. Three peaks with the molecular weights of 4657.56, 2955.95, and 3278.00 were detected which are potentially useful for differentiating RCC and renal benign masses. Using serial method combining CT and the decision tree based on these three proteins improves the sensitivity and positive predictive values of diagnosing RCC to 100%.
- 1 March 2008
- Vol. 27 (3)
[Serum proteomic spectra of esophageal squamous cell carcinoma patients analyzed with IMAC3 protein chip].
Serum protein fingerprinting technology can help to identify the molecular changes related to esophageal carcinogenesis. This study was to screen serum markers and establish the predictive models that may be of help to serologic diagnosis of esophageal squamous cell carcinoma (ESCC).
- 1 March 2008
- Vol. 27 (3)
[Serum proteomic spectra of esophageal squamous cell carcinoma patients analyzed with IMAC3 protein chip].
Serum protein fingerprinting technology can help to identify the molecular changes related to esophageal carcinogenesis. This study was to screen serum markers and establish the predictive models that may be of help to serologic diagnosis of esophageal squamous cell carcinoma (ESCC).
- Open Access
- 1 January 2008
- Published by Baishideng Publishing Group Inc. in World Chinese Journal of Digestology
- Vol. 16 (19) , 2166
Differential expression of serum proteomic spectra in rat model of pancreatic intraepithelial neoplasia and dimethylbenzanthracene-induced pancreatic carcinoma
- 1 January 2008
- Published by Baishideng Publishing Group Inc. in World Chinese Journal of Digestology
- Vol. 16 (19) , 2166
Open AccessDifferential expression of serum proteomic spectra in rat model of pancreatic intraepithelial neoplasia and dimethylbenzanthracene-induced pancreatic carcinoma